Purinergic signaling (Homo sapiens)

From WikiPathways

Revision as of 04:49, 27 July 2022 by Egonw (Talk | contribs)
Jump to: navigation, search
41915, 20, 21cAMP down due to ADORA3->Cardiac muscle relaxation->Smooth muscle contraction->Cardioprotective in cardiac ischemia->Inhibition of neutrophil degranulationAgonist bindingAntagonist bindingPhysiological downstream effects in target tissuecations in generalcAMP up due to ADORA1->Bronchoconstriction->Afferent arteriolar constriction in Kidney-> decreased heart rateP1 or Adenosine receptorsPro-InflammationADORA1stimulatescAMP up due to ADORA2A->Coronary artery vasodilatation->Decreased dopaminergic activity in CNS->Inhibition of central neuron excitation.via cGMP and Adenylyl cyclasechannel permeability for:G protein couplingGi/oprotein familyUTPN6-CyclopentyladenosineP2RY10CGS-21680PSB 36P2RX7MRS-1754MRE3008F202-Cl-IB-MECAGNAO1PANX1P2RY13TheophyllineUDPGNAZADORA2BP2RX6PSB 10P2RX2GR 79236P2RX3N6-3-methoxyl-4-hydroxybenzyl adenine ribosideDPCPXATPCP-532,903VUF-5574CaffeineP2RX4SCH-58261ATL-146eP2RX1GNAI3GNAT3PSB-11GNAT2PSB-0788LUF-5835LUF-5845SCH-442,416AMPSDZ WAG 994P2RY2ADORA3PSB-1115IstradefyllineGNAT1CPXUDP-glucose2'-MeCCPAADPLPAR4AdenosineP2RY14MRS-1220MRS-1191LPAR6MRS-1523GNAI1P2RY8IB-MECAP2RY12LPARegadenosonADORA2AP2RY6P2RY11cAMPHEMADOP2RX5MRS-13348-Phenyl-1,3-dipropylxanthineMRS-1706CVT-6883MRS-3558N-methyl-D-glucaminePSB-603P2RY1ADORA1MRS-3777BAY 60–6583ZM-241,385P2RY45'-N-ethylcarboxamidoadenosineGq/11CCPAP2Y groupP2X groupligand gated ion channels1416861041617117316164421319GiGNASBLU-59375, 9Gefapixant12OpiranserinIvermectin19Zn(2+)SuraminPPADS 1919L-Glutathione1, 18Ca(2+)19Mg(2+)Cu(2+)19GNAI219cAMP up due to ADORA2B ->Bronchoconstriction->BronchospasmADORA3inhibitsCa(2+)


Description

Purinergic signaling is involved in several processes including neurologic, endocrine, and immune system signaling.

Try the New WikiPathways

View approved pathways at the new wikipathways.org.

Quality Tags

Ontology Terms

 

Bibliography

View all...
  1. Richards D, Gever JR, Ford AP, Fountain SJ; ''Action of MK-7264 (gefapixant) at human P2X3 and P2X2/3 receptors and in vivo efficacy in models of sensitisation.''; Br J Pharmacol, 2019 PubMed Europe PMC Scholia
  2. Klotz KN, Lohse MJ, Schwabe U, Cristalli G, Vittori S, Grifantini M; ''2-Chloro-N6-[3H]cyclopentyladenosine ([3H]CCPA)--a high affinity agonist radioligand for A1 adenosine receptors.''; Naunyn Schmiedebergs Arch Pharmacol, 1989 PubMed Europe PMC Scholia
  3. Zablocki JA, Wu L, Shryock J, Belardinelli L; ''Partial A(1) adenosine receptor agonists from a molecular perspective and their potential use as chronic ventricular rate control agents during atrial fibrillation (AF).''; Curr Top Med Chem, 2004 PubMed Europe PMC Scholia
  4. Freitas HR, Ferraz G, Ferreira GC, Ribeiro-Resende VT, Chiarini LB, do Nascimento JL, Matos Oliveira KR, Pereira Tde L, Ferreira LG, Kubrusly RC, Faria RX, Herculano AM, Reis RA; ''Glutathione-Induced Calcium Shifts in Chick Retinal Glial Cells.''; PLoS One, 2016 PubMed Europe PMC Scholia
  5. North RA; ''Molecular physiology of P2X receptors.''; Physiol Rev, 2002 PubMed Europe PMC Scholia
  6. Matsufuji H, Ueo H, Mori M, Kuwano H, Sugimachi K; ''Enhancement of esophageal carcinogenesis induced in rats by N-amyl-N-methylnitrosamine in the presence of 12-O-tetradecanoylphorbol-13-acetate.''; J Natl Cancer Inst, 1987 PubMed Europe PMC Scholia
  7. Froestl W, Muhs A, Pfeifer A; ''Cognitive enhancers (nootropics). Part 1: drugs interacting with receptors.''; J Alzheimers Dis, 2012 PubMed Europe PMC Scholia
  8. Cerqueira MD; ''The future of pharmacologic stress: selective A2A adenosine receptor agonists.''; Am J Cardiol, 2004 PubMed Europe PMC Scholia
  9. Marucci G, Dal Ben D, Buccioni M, Martí Navia A, Spinaci A, Volpini R, Lambertucci C; ''Update on novel purinergic P2X3 and P2X2/3 receptor antagonists and their potential therapeutic applications.''; Expert Opin Ther Pat, 2019 PubMed Europe PMC Scholia
  10. Hutchinson SA, Scammells PJ; ''A(1) adenosine receptor agonists: medicinal chemistry and therapeutic potential.''; Curr Pharm Des, 2004 PubMed Europe PMC Scholia
  11. Garceau D, Chauret N; ''BLU-5937: A selective P2X3 antagonist with potent anti-tussive effect and no taste alteration.''; Pulm Pharmacol Ther, 2019 PubMed Europe PMC Scholia
  12. Williams M, Braunwalder A, Erickson TJ; ''Evaluation of the binding of the A-1 selective adenosine radioligand, cyclopentyladenosine (CPA), to rat brain tissue.''; Naunyn Schmiedebergs Arch Pharmacol, 1986 PubMed Europe PMC Scholia
  13. Baraldi PG, Tabrizi MA, Fruttarolo F, Romagnoli R, Preti D; ''Recent improvements in the development of A(2B) adenosine receptor agonists.''; Purinergic Signal, 2008 PubMed Europe PMC Scholia
  14. Freitas HR, Reis RA; ''Glutathione induces GABA release through P2X7R activation on Müller glia.''; Neurogenesis (Austin), 2017 PubMed Europe PMC Scholia
  15. Zocchi C, Ongini E, Conti A, Monopoli A, Negretti A, Baraldi PG, Dionisotti S; ''The non-xanthine heterocyclic compound SCH 58261 is a new potent and selective A2a adenosine receptor antagonist.''; J Pharmacol Exp Ther, 1996 PubMed Europe PMC Scholia
  16. Martinson EA, Johnson RA, Wells JN; ''Potent adenosine receptor antagonists that are selective for the A1 receptor subtype.''; Mol Pharmacol, 1987 PubMed Europe PMC Scholia
  17. Moresco RM, Todde S, Belloli S, Simonelli P, Panzacchi A, Rigamonti M, Galli-Kienle M, Fazio F; ''In vivo imaging of adenosine A2A receptors in rat and primate brain using [11C]SCH442416.''; Eur J Nucl Med Mol Imaging, 2005 PubMed Europe PMC Scholia
  18. Mayer CA, Haxhiu MA, Martin RJ, Wilson CG; ''Adenosine A2A receptors mediate GABAergic inhibition of respiration in immature rats.''; J Appl Physiol (1985), 2006 PubMed Europe PMC Scholia
  19. Tracey WR, Magee WP, Oleynek JJ, Hill RJ, Smith AH, Flynn DM, Knight DR; ''Novel N6-substituted adenosine 5'-N-methyluronamides with high selectivity for human adenosine A3 receptors reduce ischemic myocardial injury.''; Am J Physiol Heart Circ Physiol, 2003 PubMed Europe PMC Scholia
  20. Daly JW, Jacobson KA, Ukena D; ''Adenosine receptors: development of selective agonists and antagonists.''; Prog Clin Biol Res, 1987 PubMed Europe PMC Scholia
  21. Li Q, Ye K, Blad CC, den Dulk H, Brouwer J, Ijzerman AP, Beukers MW; ''ZM241385, DPCPX, MRS1706 are inverse agonists with different relative intrinsic efficacies on constitutively active mutants of the human adenosine A2B receptor.''; J Pharmacol Exp Ther, 2007 PubMed Europe PMC Scholia

History

View all...
CompareRevisionActionTimeUserComment
134667view14:44, 25 July 2024Ash iyeradded missing annotation to datanodes.
134647view08:58, 24 July 2024EgonwRemoved la
134630view11:21, 23 July 2024EweitzMove legend to corner
134629view11:20, 23 July 2024EweitzRefine legend
134628view11:15, 23 July 2024EweitzModified description
123440view04:49, 27 July 2022EgonwCID of the active ingredient
110333view06:41, 6 May 2020FehrhartOntology Term : 'nucleoside and nucleotide mediated signaling pathway' added !
110280view07:15, 2 May 2020EgonwRemoved whitespace from PubChem identifiers.
110275view07:02, 2 May 2020EgonwReplaced secondary ChEBI identifiers with a primary identifiers.
110157view06:34, 22 April 2020FehrhartWork in progress
110126view10:32, 19 April 2020FehrhartWork in progress
110125view10:18, 19 April 2020FehrhartWork in progress
110112view15:26, 17 April 2020FehrhartWork in progress
110110view10:47, 17 April 2020FehrhartOntology Term : 'nucleotide signaling via the purinergic P2Y receptors.' added !
110109view09:43, 17 April 2020FehrhartWork in progress
110108view09:33, 17 April 2020FehrhartNew pathway

External references

DataNodes

View all...
NameTypeDatabase referenceComment
2'-MeCCPAMetabolite122173097 (PubChem-compound)
2-Cl-IB-MECAMetabolite2-Cl-IB-MECA
5'-N-ethylcarboxamidoadenosineMetabolite3086599 (PubChem-compound)
8-Phenyl-1,3-dipropylxanthineMetabolite90477827 (PubChem-compound)
ADORA1GeneProductENSG00000163485 (Ensembl)
ADORA2AGeneProductENSG00000128271 (Ensembl)
ADORA2BGeneProductENSG00000170425 (Ensembl)
ADORA3GeneProductENSG00000282608 (Ensembl)
ADPMetabolite16761  (ChEBI)
AMPMetabolite16027 (ChEBI)
ATL-146eMetabolite9805430 (PubChem-compound)
ATPMetabolite15422 (ChEBI)
AdenosineMetabolite16335 (ChEBI)
BAY 60–6583Metabolite11717831 (PubChem-compound)
BLU-5937Metabolite
CCPAMetabolite123807 (PubChem-compound)
CGS-21680Metabolite3086599 (PubChem-compound)
CP-532,903Metabolite10479002 (PubChem-compound)
CPXMetabolite1917 (PubChem-compound) 8-Cyclopentyl-1,3-dimethylxanthine
CVT-6883Metabolite11270783 (PubChem-compound)
Ca(2+)MetaboliteCHEBI:29108 (ChEBI)
CaffeineMetabolite27732 (ChEBI)
Cu(2+)MetaboliteCHEBI:29036 (ChEBI)
DPCPX


Metabolite73282 (ChEBI) 8-Cyclopentyl-1,3-dipropylxanthine
GNAI1GeneProductENSG00000127955 (Ensembl)
GNAI2GeneProductENSG00000114353 (Ensembl)
GNAI3GeneProductENSG00000065135 (Ensembl)
GNAO1GeneProductENSG00000087258 (Ensembl)
GNASGeneProductENSG00000087460 (Ensembl) Gs alpha subunit (also Gαs, Gsα)
GNAT1GeneProductENSG00000114349 (Ensembl)
GNAT2GeneProductENSG00000134183 (Ensembl)
GNAT3GeneProductENSG00000214415 (Ensembl)
GNAZGeneProductENSG00000128266 (Ensembl)
GR 79236Metabolite9884817 (PubChem-compound)
GefapixantMetabolite24764487 (PubChem-compound)
GiGeneProduct
Gq/11GeneProduct
HEMADOMetabolite10981286 (PubChem-compound) 2-(1-Hexynyl)-N-methyladenosine
IB-MECAMetabolite123683 (PubChem-compound) CF-101
IstradefyllineMetabolite5311037 (PubChem-compound)
IvermectinMetabolite9812710 (PubChem-compound)
L-GlutathioneMetaboliteCHEBI:16856 (ChEBI)
LPAMetabolite132742 (ChEBI) Lysophosphatidic acid
LPAR4GeneProductENSG00000147145 (Ensembl)
  • P2RY9
  • GPR23
LPAR6GeneProductENSG00000139679 (Ensembl)
LUF-5835MetaboliteLUF-5835
LUF-5845MetaboliteLUF-5845
MRE3008F20Metabolite5310960 (PubChem-compound)
MRS-1191Metabolite393594 (PubChem-compound)
MRS-1220Metabolite393595 (PubChem-compound)
MRS-1334Metabolite10324445 (PubChem-compound)
MRS-1523Metabolite3661570 (PubChem-compound)
MRS-1706Metabolite5139184 (PubChem-compound)
MRS-1754Metabolite6603931 (PubChem-compound)
MRS-3558Metabolite11248240 (PubChem-compound)
MRS-3777Metabolite11771279 (PubChem-compound)
Mg(2+)MetaboliteCHEBI:18420 (ChEBI)
N-methyl-D-glucamineMetaboliteCHEBI:59732 (ChEBI)
N6-3-methoxyl-4-hydroxybenzyl adenine ribosideMetaboliteB2
N6-CyclopentyladenosineMetabolite657378 (PubChem-compound)
OpiranserinMetabolite71566778 (PubChem-compound)
P2RX1GeneProductENSG00000108405 (Ensembl)
P2RX2GeneProductENSG00000187848 (Ensembl)
P2RX3GeneProductENSG00000109991 (Ensembl)
P2RX4GeneProductENSG00000135124 (Ensembl)
P2RX5GeneProductENSG00000083454 (Ensembl)
P2RX6GeneProductENSG00000099957 (Ensembl)
P2RX7GeneProductENSG00000089041 (Ensembl)
P2RY10GeneProductENSG00000078589 (Ensembl)
P2RY11GeneProductENSG00000244165 (Ensembl)
P2RY12GeneProductENSG00000169313 (Ensembl)
P2RY13GeneProductENSG00000181631 (Ensembl)
P2RY14GeneProductENSG00000174944 (Ensembl)
P2RY1GeneProductENSG00000169860 (Ensembl)
P2RY2GeneProductENSG00000175591 (Ensembl)
P2RY4GeneProductENSG00000186912 (Ensembl)
P2RY6GeneProductENSG00000171631 (Ensembl)
P2RY8GeneProductENSG00000182162 (Ensembl)
PANX1GeneProductENSG00000110218 (Ensembl)
PPADS Metabolite6093163 (PubChem-compound) pyridoxalphosphate-6-azophenyl-2',4'-disulfonic acid
PSB 10Metabolite10318703 (PubChem-compound)
PSB 36Metabolite9864310 (Chemspider)
  • 1-butyl-8-(3- noradamantyl)-3-(3-hydroxypropyl)xanthine
  • 1-Butyl-3-(3-hydroxypropyl)-8-(tricyclo[3.3.1.03,7]non-3-yl)-3,7-dihydro-1H-purine-2,6-dione
PSB-0788Metabolite44186581 (PubChem-compound)
PSB-1115Metabolite5311479 (PubChem-compound)
PSB-11MetabolitePSB-11
PSB-603MetabolitePSB-603
RegadenosonMetabolite219024 (PubChem-compound)
SCH-442,416Metabolite10668061 (PubChem-compound)
SCH-58261Metabolite176408 (PubChem-compound)
SDZ WAG 994Metabolite18755269 (PubChem-compound)
SuraminMetabolite5361 (PubChem-compound)
TheophyllineMetabolite28177 (ChEBI)
UDP-glucoseMetabolite46229 (ChEBI)
UDPMetabolite58223 (ChEBI)
UTPMetabolite15713 (ChEBI)
VUF-5574Metabolite4046493 (PubChem-compound)
ZM-241,385Metabolite176407 (PubChem-compound)
Zn(2+)MetaboliteCHEBI:29105 (ChEBI)
cAMPMetaboliteCHEBI:17489 (ChEBI)

Annotated Interactions

No annotated interactions

Retrieved from "https://classic.wikipathways.org/index.php/Pathway:WP4900"
Personal tools